Abstract:
Background: Lung carcinoma remains one of the leading causes of cancer-related mortality worldwide, largely due to late-stage presentation and therapeutic resistance. Increasing evidence suggests that cancer stem cells (CSCs) contribute to tumor initiation, progression, metastasis, and treatment failure. CD133 is a well-recognized CSC marker that has been implicated in aggressive tumor behavior in several malignancies. This study aimed to evaluate the expression of CD133 in lung carcinoma and determine its association with clinicopathological parameters, particularly tumor stage.
Methods: A prospective pilot study was conducted on 55 newly diagnosed, treatment-naïve lung carcinoma patients presenting to a tertiary care center between November 2015 and April 2016. Formalin-fixed paraffin-embedded tissue specimens obtained from bronchoscopic or biopsy procedures were subjected to routine histopathological examination and immunohistochemical staining for CD133. CD133 expression was categorized according to the percentage of positive tumor cells and correlated with demographic characteristics, histological subtype, and clinical stage. Statistical analysis was performed using SPSS software, with significance established at p < 0.05.
Results: The study cohort comprised 42 males and 13 females with a mean age of 53.5 ± 10.8 years. Squamous cell carcinoma was the predominant histological subtype (61.8%), followed by adenocarcinoma (21.8%). CD133 expression was detected in 72.7% of cases. A progressive increase in CD133 positivity was observed with advancing clinical stage, being present in 62.5% of Stage I, 90% of Stage II, 94.1% of Stage III, and 100% of Stage IV tumors. CD133 expression score demonstrated a significant positive association with tumor stage (p < 0.001). The marker exhibited a sensitivity of 88.6%, specificity of 90.9%, positive predictive value of 97.5%, and overall diagnostic accuracy of 89.1% for identifying clinically advanced disease. No statistically significant association was observed between CD133 expression and histological subtype.
Conclusions: CD133 expression shows a strong positive correlation with advancing stage of lung carcinoma and may serve as a useful prognostic biomarker for tumor progression. The findings support the potential role of CSC-related markers in risk stratification and prognostication of lung cancer patients. Larger multicentric studies are warranted to validate these observations and explore the utility of CD133 as a therapeutic target in precision oncology.
Biography:
Neema Tiwari did her MBBS and MD in Pathology in Pathology from Eras Lucknow Medical college and Hospital, She is has worked as Senior Resident, Pathology in department of clinical hematology and hemato-oncology, King George Medical University, India and Post Graduate Institute of Child Health Noida, UP and has 4 years post PG experience. She is currently working as Assistant Professor in Post graduate Institute of Child Health, Noida. She has done numerous intramural and extramural (ICMR,DST)research projects and has many national and international publications in indexed and peer reviewed journals(>40) to her credit. She is a reviewer for 3 journals to of which are pubmed indexed. She has presented papers in IAP,ICC and CAP conferences. She has recently presented a poster on MDS in the ISHBT-EHS TUTORIAL-2018 held in India. She is an ICO Fellow from Barcelona Spain in Molecular pathology/hematology.
She has also co-authored 2 books titled
-Analysis of various patterns of leukemia in Indian population-Neema Tiwari, Sunita Tiwari (Lambert publications, now available in Barns and Noble website, Amazon, flipkart)-2018
-Manual of Hematology, Ahuja publishers-2021
Hematology Made easy-2024(Questvision publication)
-3 Book chapters in 3 books under publication
She has her youtube channel for teaching Pathology to postgraduate residents in her name with >1500 followers
She in International ambassador for College of American Pathologists in India for current 2 years
She is an International Observer(Pathology under Dr Travis and Dr Antenescou) alumni in Memorial Sloan Kettering Cancer Centre, New York, USA
She has pursued short term fellowship in Molecular and Cytogenetics from Joseph Carrera leukemia research center,Barcelona,Spain as ICO Fellow.
Member European hematology association, Junior Member CAP, Member ISHBT,Member ESP
Copyright 2024 Mathews International LLC All Rights Reserved
